Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients-PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT. (PubMed, Rev Med Virol) - Apr 1, 2026 - "The number of available antiviral drugs for HCMV is expanding, and letermovir primary prophylaxis is increasingly being adopted due to its favourable safety profile...The administration of HCMV-specific T cell products, generated through ex vivo expansion of donor-derived or partially HLA matched, third party HCMV-specific T cells, have demonstrated efficacy in combatting clinically significant HCMV infection in clinical trials. Adoptive HCMV-specific T cell therapies represent a powerful alternative approach for managing drug resistant HCMV infections in allo-HSCT recipients and reducing the reliance on antiviral pharmacotherapies."
Journal • Review • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
Allison Abendroth; Barry Slobedman; Danya Kaplan; David J Gottlieb; Emily Blyth; Gaurav Sutrave; Lauren Stern; Michelle K Yong
|